HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists have become widely prescribed for weight loss, with clinical data supporting meaningful weight reduction in eligible patients. However, accessing appropriate treatment requires understanding your metabolic baseline, health status, and individual factors that may influence suitability and response.

PlexusDx emphasizes precision wellness by helping patients understand their metabolic context before starting GLP-1 therapy. Biomarker assessment and genetic insights into peptide pathways may support more targeted conversations with your provider about whether GLP-1 is appropriate for your specific situation.

How GLP-1 Works and What Clinical Evidence Shows

GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone regulating appetite, blood sugar, and gastric emptying. Clinical trials demonstrate weight reductions of 15–22% depending on baseline BMI, duration, and dose achieved.

These medications also improve cardiometabolic markers including fasting glucose, HbA1c, and blood pressure in many patients. Efficacy varies—some patients achieve substantial weight loss while others experience modest changes, underscoring the importance of baseline assessment and provider monitoring.

Essential Biomarkers to Assess Before Starting GLP-1

Before initiating GLP-1 therapy, understanding your metabolic baseline supports informed decision-making with your provider. Key biomarkers provide context about glucose regulation, renal function, thyroid status, and cardiovascular risk—all relevant to GLP-1 candidacy and monitoring strategy.

Biomarker Category Why It Matters for GLP-1
Fasting glucose and HbA1c Establishes baseline glucose control and metabolic state; guides dose titration and monitoring frequency.
Renal function (eGFR, creatinine) GLP-1 medications are renally cleared; impaired function may require dose adjustment or closer monitoring.
Thyroid function (TSH, free T4) Contraindication screening: contraindicated in personal or family history of medullary thyroid cancer.
Lipid panel (total cholesterol, LDL, HDL, triglycerides) Establishes cardiovascular baseline; many patients see lipid improvements with weight loss on GLP-1.
Blood pressure and heart rate Baseline assessment ensures safe titration; some patients experience orthostatic changes during dose escalation.

Genetic Predispositions in Peptide Pathways: Context for Personalization

Genetic variation in GLP-1 receptor, GIPR, and appetite-related genes may influence how your body responds to GLP-1 therapy. PlexusDx Precision Peptide Genetic Test examines key variants—including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609—to reveal predispositions in peptide signaling pathways.

These genetic insights may help provide context for your provider about potential responder profiles and dosing considerations. However, genetics does not predict exact medication response—individual factors including lifestyle, comorbidities, and medication interactions play equally important roles. Your qualified healthcare provider should interpret results alongside your complete clinical picture.

Who Should Consider GLP-1, and Important Eligibility Screening

GLP-1 therapy may be considered for adults with BMI ≥27 kg/m² with weight-related comorbidities or BMI ≥30 kg/m² regardless of comorbidities, according to clinical guidelines. Patients should be motivated to adopt lifestyle changes and have no contraindications including personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.

Pregnancy, breastfeeding, severe diabetic retinopathy, acute pancreatitis, and uncontrolled psychiatric illness represent additional screening considerations. Your provider must evaluate your full medical history, medications, and social context to determine suitability. Compounded GLP-1 options through licensed 503A pharmacies may offer cost flexibility, but medical clearance from a qualified provider remains essential before any initiation.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test may help provide context by revealing your predispositions across GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—variants relevant to peptide hormone pathways and appetite regulation. This information can support a more informed conversation with your provider about whether GLP-1 is strategically aligned with your metabolic biology.

The genetic test reveals predispositions within peptide pathways, not exact medication response. Environmental factors, adherence, concurrent medications, and lifestyle changes remain equally critical determinants of real-world outcomes. Genetic context should be interpreted by your qualified healthcare provider as one piece of a comprehensive assessment.

Understanding your genetic predispositions alongside baseline biomarkers creates a more complete clinical picture. This information may support more targeted provider discussions about GLP-1 candidacy, initial dosing strategy, monitoring frequency, and whether alternative or complementary approaches warrant consideration alongside medication.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the typical cost of GLP-1 for weight loss, and how does PlexusDx pricing compare?

Brand GLP-1 medications cost $900–$1,300 monthly. PlexusDx compounded semaglutide injection ranges $179–$229/month, and compounded tirzepatide injection $229–$309/month, sourced from licensed 503A pharmacies. Consult your provider about medical necessity and coverage eligibility.

How long does it take to see weight loss results with GLP-1?

Most patients notice appetite reduction within 1–2 weeks of starting GLP-1. Measurable weight loss typically emerges by 4–8 weeks, with progressive results continuing over 12–16 weeks as doses escalate. Individual timelines vary based on baseline metabolism and adherence.

Can the Precision Peptide Genetic Test predict whether I will respond well to GLP-1?

The test reveals genetic predispositions in peptide pathways that may provide clinical context, but does not predict exact medication response. Lifestyle, comorbidities, dose achieved, and medication adherence significantly influence real-world outcomes. Interpretation requires a qualified healthcare provider.

What are the most common side effects, and when do they typically resolve?

Nausea, vomiting, diarrhea, and constipation occur in 20–40% of patients, most commonly during dose escalation. Side effects typically subside within 2–4 weeks as your body adjusts. Slower titration and dietary modifications may minimize severity. Persistent symptoms warrant provider reassessment.

How often should I have lab work while on GLP-1 therapy?

Your provider should order baseline labs before starting and reassess metabolic markers, renal function, and glucose control at 4–12 week intervals during initial titration. Long-term monitoring frequency decreases once stable on maintenance dose, typically every 3–6 months.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.